|Bid||142.75 x 500|
|Ask||142.90 x 300|
|Day's Range||141.68 - 142.92|
|52 Week Range||91.05 - 142.92|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.56%|
While most of the sectors have flourished over the past decade, consumer discretionary and information technology have led the way .
First Trust Advisors L.P. a global exchange-traded fund provider and asset manager, announced that the Mexican pension funds investment regulator, La Comisión Nacional del Sistema de Ahorro para el Retiro , has approved four additional First Trust ETFs for sale to Mexican funded pensions, known as AFORES.
The following is original research by ARK's Genomic Revolution Analyst, Manisha Samy . Genome-Editing During the past decade, technology breakthroughs enabling the modification of complex genomes have changed the primary goal of research in ...
Prime Minister May Looks to Bolster the Sector Earlier this year, Prime Minister Theresa May earmarked life sciences as one of five areas critical to the UK’s economic growth and commissioned a proposal on how to bolster the sector, especially as the ...
Apart from Gilead Sciences' (GILD) antiviral drugs portfolio, the company also includes drugs from therapeutic areas like cardiovascular, inflammation, oncology, and respiratory products in its portfolio....
Key U.S. index funds rallied to big gains, led by Apple's 2% jump ahead of its Tuesday product launch event.
On April 29, 2016, the FDA approved Acadia Pharmaceuticals’ (ACAD) Nuplazid (pimavanserin) as a first therapy for treating patients with Parkinson’s disease (or PD) psychosis.
Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a "hold."
In April 2017, the FDA approved Neurocrine Biosciences’ (NBIX) Ingrezza (valbenazine) as the first drug for the treatment of tardive dyskinesia.
The Zacks Analyst Blog Highlights: SPDR Technology ETF, SPDR S&P Biotech ETF, First Trust NYSE Arca Biotechnology Index Fund, BioShares Biotechnology Products ETF and SPDR Healthcare ETF
Todd Hagopian’s Biotech Fund is up over 30% as many of his stock picks have taken off after President Trump and Senate Republicans turned their attention to healthcare.